EDGAR·FLOW

PLIANT THERAPEUTICS, INC. — Form 8-K

Filed July 13, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Form 8-K filed 7/13/2026 disclosing Item 5.02 (officer/director departure and compensatory arrangements) for period ending 7/9/2026. Specific names, dollar amounts, titles, and arrangement details are not visible in the filing header metadata provided.
Why this rating

Leadership change is material event, but absence of concrete details (counterparty, amounts, terms) prevents full assessment. For $69.5M company, impact depends on officer seniority and severance magnitude—unknowable here.

Extracted items
View original filing on SEC.gov ↗ PLRX · stock on Yahoo Finance ↗

See more from July 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.